CISLIEVA 50MG ( Cisplatin Injection IP 50mg )

CISLIEVA 50 mg contains Cisplatin, a platinum-based chemotherapy (anticancer) medicine. It works by forming DNA cross-links, which inhibit DNA replication and transcription, leading to death of rapidly dividing cancer cells. Cisplatin is widely used in many solid tumors.

Cisplatin Injection is indicated for the treatment of:

• Testicular cancer

• Ovarian cancer

• Bladder cancer

• Head and neck cancers

• Lung cancer (NSCLC and SCLC)

• Cervical cancer

• Gastric and esophageal cancers

Common side effects:

• Severe nausea and vomiting

• Kidney toxicity (nephrotoxicity)

• Hearing loss or ringing in ears (ototoxicity)

• Myelosuppression

• Electrolyte disturbances (↓ magnesium, potassium)

• Peripheral neuropathy

Serious side effects:

• Acute renal failure

• Severe ototoxicity

• Hypersensitivity reactions

• Neurotoxicity

 Adequate hydration and electrolyte monitoring are mandatory with cisplatin therapy.

Dosage depends on body surface area (BSA), cancer type, and protocol.

Common dosing schedules:

• 50–100 mg/m² IV every 3–4 weeks

• 20 mg/m²/day IV for 5 consecutive days every 3–4 weeks

Given as slow intravenous infusion with pre- and post-hydration, under strict oncologist supervision.